Regular paperIncreased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban
Section snippets
Acknowledgements
The investigators thank Barbara McVan, RN, Patricia Q. Baumann, MS, Michaeleanne Rowen, RN, Danielle C. Tardiff, RN, Shiv Kapoor, PhD, Jaromir Bobek, MS, Debbie Regan, RN, and Cyndi Dietrich, MS, without whom completion of the studies would not have been possible.
References (11)
- et al.
Suboptimal early inhibition of platelets by treatment with tirofibanimplications for coronary interventions
Am J Cardiol
(2002) - et al.
Blood clotting in minimally altered whole blood
Blood
(1996) - et al.
Determination of MK-383, a non-peptide fibrinogen receptor antagonist in plasma and urine by radioimmunoassay
J Pharm Biomed Anal
(1994) - et al.
Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting
J Am Coll Cardiol
(2001) - et al.
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
N Engl J Med
(2001)
There are more references available in the full text version of this article.
Cited by (0)
Copyright © 2003 Excerpta Medica Inc. All rights reserved.